{"entity": "researcher", "timestamp": "2026-08-20T21:19:18.401Z", "family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "affiliations": ["K.G. Jebsen Colorectal Cancer Research Centre, Division for Cancer Medicine, Oslo University Hospital, Norway.", "Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859"}}, "publications": [{"entity": "publication", "iuid": "c429155a65c2485e889f0c8355749a7e", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c429155a65c2485e889f0c8355749a7e.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c429155a65c2485e889f0c8355749a7e"}}, "title": "Validation of fibroblast activation protein and \u03b1-smooth muscle actin as prognostic biomarkers in prostate cancer through AI-assisted image analysis of dual-marker IHC.", "authors": [{"family": "S\u00e4il\u00e4", "given": "Jenni", "initials": "J", "orcid": "0000-0001-7510-3483", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/7ea2623a64b249339bcfaf11810b7249.json"}}, {"family": "Lehto", "given": "Timo-Pekka", "initials": "TP"}, {"family": "Rannikko", "given": "Antti", "initials": "A"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Mirtti", "given": "Tuomas", "initials": "T"}, {"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}], "type": "journal article", "published": "2026-01-00", "journal": {"title": "J Pathol Clin Res", "issn": "2056-4538", "volume": "12", "issue": "1", "pages": "e70068", "issn-l": null}, "abstract": "Prostate cancer (PCa) lacks reliable and accurate tissue-based biomarkers to support prognostic stratification and clinical treatment decisions. Current diagnostic assessment, including Gleason grading, has limitations such as interobserver variability and insufficient granularity for disease aggressiveness. Fibroblast activation protein (FAP) and \u03b1-smooth muscle actin (\u03b1SMA) have emerged as putative stromal biomarkers, but their prognostic value in localised PCa has not been validated at scale. In this study, we developed a novel artificial intelligence (AI)-augmented image analysis pipeline tailored for dual-marker immunohistochemistry of FAP and \u03b1SMA, enabling automated, tissue compartment-specific quantification of biomarker expression. This deep learning model was trained and validated using digitised high-resolution whole-slide images of tissue microarrays from three prostatectomy cohorts, comprising 4,097 cores from 835 patients with comprehensive clinical follow-up data. The AI pipeline demonstrated high accuracy in detecting epithelial, stromal, and immune compartments, as well as in quantifying FAP and \u03b1SMA signals. We validated stromal FAP as a robust prognostic marker consistently associated with adverse clinical outcomes, including earlier biochemical recurrence, metastasis, and cancer-specific death. Epithelial FAP and stromal \u03b1SMA showed additional prognostic associations in selected analyses, particularly in MRI-visible tumours. Our findings reinforce the biological and clinical relevance of stromal FAP in the prostate tumour microenvironment. By enabling standardised and scalable biomarker quantification, our newly developed AI-assisted workflow advances the clinical utility of FAP and \u03b1SMA and demonstrates the power of integrating digital pathology with biomarker quantification. This study represents a critical step toward implementing stromal biomarkers in routine PCa diagnostics and underscores the potential of AI-enhanced histopathology in advancing precision oncology.", "doi": "10.1002/2056-4538.70068", "pmid": "41410015", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12712236"}], "notes": [], "created": "2026-08-20T06:27:10.832Z", "modified": "2026-08-20T06:27:10.944Z"}, {"entity": "publication", "iuid": "a2d4d6d4a5c5405aa4e890d419216721", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a2d4d6d4a5c5405aa4e890d419216721.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a2d4d6d4a5c5405aa4e890d419216721"}}, "title": "Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma.", "authors": [{"family": "Roos-Mattila", "given": "Matilda", "initials": "M", "orcid": "0000-0002-2834-3211", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f9dd8feca623400d8e0c17b2725b6dc7.json"}}, {"family": "Kallio", "given": "Pauliina", "initials": "P", "orcid": "0000-0001-6374-6203", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/341466e88f824af587e257b73582d6dd.json"}}, {"family": "Luck", "given": "Tamara J", "initials": "TJ"}, {"family": "Polso", "given": "Minttu", "initials": "M"}, {"family": "Kumari", "given": "Romika", "initials": "R"}, {"family": "Mikkonen", "given": "Piia", "initials": "P"}, {"family": "V\u00e4lim\u00e4ki", "given": "Katja", "initials": "K", "orcid": "0000-0001-9117-7589", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/6e4948127dec4455803fa8c74fefbde5.json"}}, {"family": "Malmstedt", "given": "Minna", "initials": "M"}, {"family": "Ellonen", "given": "Pekka", "initials": "P"}, {"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}, {"family": "Heckman", "given": "Caroline A", "initials": "CA", "orcid": "0000-0002-4324-8706", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/a0490f5eb61a4d92a44815d03de84af4.json"}}, {"family": "Mustonen", "given": "Harri", "initials": "H", "orcid": "0000-0001-5632-6796", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f009308cd84542ae8c384fbfe87501d2.json"}}, {"family": "Puolakkainen", "given": "Pauli A", "initials": "PA"}, {"family": "Alitalo", "given": "Kari", "initials": "K", "orcid": "0000-0002-7331-0902", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/d9a1a31264694e4fba6026b293655ff0.json"}}, {"family": "Kallioniemi", "given": "Olli", "initials": "O", "orcid": "0000-0002-3231-0332", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cb8605b07c884323afe4e1f2da37a031.json"}}, {"family": "Mirtti", "given": "Tuomas", "initials": "T", "orcid": "0000-0003-0455-9891", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c1963bc5086f4b45b9a48cb60115d578.json"}}, {"family": "Rannikko", "given": "Antti S", "initials": "AS"}, {"family": "Pieti\u00e4inen", "given": "Vilja M", "initials": "VM", "orcid": "0000-0003-3125-2406", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/6d24125e51334b94bce4ef70fed1e585.json"}}, {"family": "Sepp\u00e4nen", "given": "Hanna E", "initials": "HE"}], "type": "journal article", "published": "2024-10-20", "journal": {"title": "Commun Biol", "issn": "2399-3642", "volume": "7", "issue": "1", "pages": "1355", "issn-l": "2399-3642"}, "abstract": "Clear-cell renal cell carcinoma (ccRCC) is the most common origin of pancreatic metastases (PM). Distinct genomic aberrations, favorable prognosis, and clinical observations on high angiogenesis, and succeeding tyrosine kinase inhibitor (TKI) sensitivity have been reported in PM-ccRCC. However, no functional or single-cell studies have been conducted thus far. We recruited five PM-ccRCC patients and investigated the genomic, single-cell transcriptomic, and drug sensitivity profiles of their patient-derived cells (PDCs). The PM depicted both expected and novel genomic alterations. Further, the transcriptomics differed from both primary and metastatic ccRCC, with upregulations of the PI3K/mTOR and - supporting the clinical observations - angiogenesis pathways. Data integration at pathway level showed that transcriptomics explained drug sensitivities the best. Accordingly, PM-ccRCC PDCs shared sensitivity to many PI3K/mTOR inhibitors. Altogether, we show distinct genomic and transcriptomic signatures in PM-ccRCC, highlight the superiority of transcriptomics in interpreting drug sensitivities, and encourage the use of TKIs and PI3K/mTOR inhibitors in PM-ccRCC.", "doi": "10.1038/s42003-024-07004-9", "pmid": "39427059", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11490566"}, {"db": "pii", "key": "10.1038/s42003-024-07004-9"}], "notes": [], "created": "2026-08-20T09:25:17.594Z", "modified": "2026-08-20T09:25:17.901Z"}, {"entity": "publication", "iuid": "95296c52bd3b4c108f944528c87402fb", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/95296c52bd3b4c108f944528c87402fb.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/95296c52bd3b4c108f944528c87402fb"}}, "title": "Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.", "authors": [{"family": "Murum\u00e4gi", "given": "Astrid", "initials": "A", "orcid": "0000-0002-7797-188X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/44376ab482ab42c3a4f3bbc68c27c97d.json"}}, {"family": "Ungureanu", "given": "Daniela", "initials": "D"}, {"family": "Khan", "given": "Suleiman", "initials": "S"}, {"family": "Arjama", "given": "Mariliina", "initials": "M"}, {"family": "V\u00e4lim\u00e4ki", "given": "Katja", "initials": "K"}, {"family": "Ianevski", "given": "Aleksandr", "initials": "A"}, {"family": "Ianevski", "given": "Philipp", "initials": "P"}, {"family": "Bergstr\u00f6m", "given": "Rebecka", "initials": "R"}, {"family": "Dini", "given": "Alice", "initials": "A", "orcid": "0000-0002-2720-4551", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3c00ed4eb41e45629cfc525e737f99c4.json"}}, {"family": "Kanerva", "given": "Anna", "initials": "A"}, {"family": "Koivisto-Korander", "given": "Riitta", "initials": "R"}, {"family": "Tapper", "given": "Johanna", "initials": "J"}, {"family": "Lassus", "given": "Heini", "initials": "H", "orcid": "0000-0003-0598-5147", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c854daf0fada43ee97951cba27414def.json"}}, {"family": "Loukovaara", "given": "Mikko", "initials": "M"}, {"family": "M\u00e4gi", "given": "Andrus", "initials": "A"}, {"family": "Hirasawa", "given": "Akira", "initials": "A"}, {"family": "Aoki", "given": "Daisuke", "initials": "D"}, {"family": "Pieti\u00e4inen", "given": "Vilja", "initials": "V", "orcid": "0000-0003-3125-2406", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/6d24125e51334b94bce4ef70fed1e585.json"}}, {"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}, {"family": "B\u00fctzow", "given": "Ralf", "initials": "R", "orcid": "0000-0003-4366-5099", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/b6e16836d19645bbbec8bb1a851a02e0.json"}}, {"family": "Aittokallio", "given": "Tero", "initials": "T", "orcid": "0000-0002-0886-9769", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/433e429e6a5b49818cf54f5fc102fff7.json"}}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}], "type": "journal article", "published": "2023-02-00", "journal": {"title": "Br. J. Cancer", "issn": "1532-1827", "volume": "128", "issue": "4", "pages": "678-690", "issn-l": "0007-0920"}, "abstract": "Many efforts are underway to develop novel therapies against the aggressive high-grade serous ovarian cancers (HGSOCs), while our understanding of treatment options for low-grade (LGSOC) or mucinous (MUCOC) of ovarian malignancies is not developing as well. We describe here a functional precision oncology (fPO) strategy in epithelial ovarian cancers (EOC), which involves high-throughput drug testing of patient-derived ovarian cancer cells (PDCs) with a library of 526 oncology drugs, combined with genomic and transcriptomic profiling. HGSOC, LGSOC and MUCOC PDCs had statistically different overall drug response profiles, with LGSOCs responding better to targeted inhibitors than HGSOCs. We identified several subtype-specific drug responses, such as LGSOC PDCs showing high sensitivity to MDM2, ERBB2/EGFR inhibitors, MUCOC PDCs to MEK inhibitors, whereas HGSOCs showed strongest effects with CHK1 inhibitors and SMAC mimetics. We also explored several drug combinations and found that the dual inhibition of MEK and SHP2 was synergistic in MAPK-driven EOCs. We describe a clinical case study, where real-time fPO analysis of samples from a patient with metastatic, chemorefractory LGSOC with a CLU-NRG1 fusion guided clinical therapy selection. fPO-tailored therapy with afatinib, followed by trastuzumab and pertuzumab, successfully reduced tumour burden and blocked disease progression over a five-year period. In summary, fPO is a powerful approach for the identification of systematic drug response differences across EOC subtypes, as well as to highlight patient-specific drug regimens that could help to optimise therapies to individual patients in the future.", "doi": "10.1038/s41416-022-02067-z", "pmid": "36476658", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9938120"}, {"db": "pii", "key": "10.1038/s41416-022-02067-z"}], "notes": [], "created": "2026-08-20T08:49:06.144Z", "modified": "2026-08-20T08:49:06.456Z"}, {"entity": "publication", "iuid": "e592453711d34172ba82290c80b6efd8", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/e592453711d34172ba82290c80b6efd8.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/e592453711d34172ba82290c80b6efd8"}}, "title": "Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features.", "authors": [{"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}, {"family": "Paavolainen", "given": "Lassi", "initials": "L"}, {"family": "Mart\u00edn-Bernab\u00e9", "given": "Alfonso", "initials": "A"}, {"family": "Papatella Araujo", "given": "Renata", "initials": "R"}, {"family": "Strell", "given": "Carina", "initials": "C", "orcid": "0000-0002-3783-7256", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f288539ea7eb406480c84ec1a5605a91.json"}}, {"family": "Mezheyeuski", "given": "Artur", "initials": "A"}, {"family": "Backman", "given": "Max", "initials": "M"}, {"family": "La Fleur", "given": "Linnea", "initials": "L"}, {"family": "Br\u00fcck", "given": "Oscar", "initials": "O"}, {"family": "Sj\u00f6lund", "given": "Jonas", "initials": "J"}, {"family": "Holmberg", "given": "Erik", "initials": "E", "orcid": "0000-0001-5107-4550", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cad9bec668814f47bce74228eef5e7e0.json"}}, {"family": "V\u00e4lim\u00e4ki", "given": "Katja", "initials": "K"}, {"family": "Brunnstr\u00f6m", "given": "Hans", "initials": "H", "orcid": "0000-0001-7402-138X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1b51d0768d1a4c31bba8cf898f962a09.json"}}, {"family": "Botling", "given": "Johan", "initials": "J"}, {"family": "Moreno-Ruiz", "given": "Pablo", "initials": "P"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Micke", "given": "Patrick", "initials": "P"}, {"family": "\u00d6stman", "given": "Arne", "initials": "A"}], "type": "journal article", "published": "2023-01-10", "journal": {"title": "J. Natl. Cancer Inst.", "issn": "1460-2105", "volume": "115", "issue": "1", "pages": "71-82", "issn-l": "0027-8874"}, "abstract": "Cancer-associated fibroblasts (CAFs) are molecularly heterogeneous mesenchymal cells that interact with malignant cells and immune cells and confer anti- and protumorigenic functions. Prior in situ profiling studies of human CAFs have largely relied on scoring single markers, thus presenting a limited view of their molecular complexity. Our objective was to study the complex spatial tumor microenvironment of non-small cell lung cancer (NSCLC) with multiple CAF biomarkers, identify novel CAF subsets, and explore their associations with patient outcome.\n\nMultiplex fluorescence immunohistochemistry was employed to spatially profile the CAF landscape in 2 population-based NSCLC cohorts (n = 636) using antibodies against 4 fibroblast markers: platelet-derived growth factor receptor-alpha (PDGFRA) and -beta (PDGFRB), fibroblast activation protein (FAP), and alpha-smooth muscle actin (\u03b1SMA). The CAF subsets were analyzed for their correlations with mutations, immune characteristics, and clinical variables as well as overall survival.\n\nTwo CAF subsets, CAF7 (PDGFRA-/PDGFRB+/FAP+/\u03b1SMA+) and CAF13 (PDGFRA+/PDGFRB+/FAP-/\u03b1SMA+), showed statistically significant but opposite associations with tumor histology, driver mutations (tumor protein p53 [TP53] and epidermal growth factor receptor [EGFR]), immune features (programmed death-ligand 1 and CD163), and prognosis. In patients with early stage tumors (pathological tumor-node-metastasis IA-IB), CAF7 and CAF13 acted as independent prognostic factors.\n\nMultimarker-defined CAF subsets were identified through high-content spatial profiling. The robust associations of CAFs with driver mutations, immune features, and outcome suggest CAFs as essential factors in NSCLC progression and warrant further studies to explore their potential as biomarkers or therapeutic targets. This study also highlights multiplex fluorescence immunohistochemistry-based CAF profiling as a powerful tool for the discovery of clinically relevant CAF subsets.", "doi": "10.1093/jnci/djac178", "pmid": "36083003", "labels": [], "xrefs": [{"db": "pii", "key": "6694853"}], "notes": [], "created": "2026-08-20T09:42:16.530Z", "modified": "2026-08-20T09:42:16.675Z"}, {"entity": "publication", "iuid": "f1c71f562b0b4f7f935549bbcde9b0e8", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/f1c71f562b0b4f7f935549bbcde9b0e8.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/f1c71f562b0b4f7f935549bbcde9b0e8"}}, "title": "E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models.", "authors": [{"family": "Bruun", "given": "Jarle", "initials": "J"}, {"family": "Eide", "given": "Peter W", "initials": "PW"}, {"family": "Bergsland", "given": "Christian Holst", "initials": "CH"}, {"family": "Bruck", "given": "Oscar", "initials": "O"}, {"family": "Svindland", "given": "Aud", "initials": "A"}, {"family": "Arjama", "given": "Mariliina", "initials": "M"}, {"family": "V\u00e4lim\u00e4ki", "given": "Katja", "initials": "K"}, {"family": "Bj\u00f8rnslett", "given": "Merete", "initials": "M"}, {"family": "Guren", "given": "Marianne G", "initials": "MG"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Nesbakken", "given": "Arild", "initials": "A"}, {"family": "Lothe", "given": "Ragnhild A", "initials": "RA", "orcid": "0000-0002-1693-1032", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9f00f9f00ecc48509b65f16e4849b8a9.json"}}, {"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}], "type": "journal article", "published": "2022-06-00", "journal": {"title": "Mol Oncol", "issn": "1878-0261", "volume": "16", "issue": "12", "pages": "2312-2329", "issn-l": "1574-7891"}, "abstract": "Cell-cell and cell-matrix adhesion proteins that have been implicated in colorectal epithelial integrity and epithelial-to-mesenchymal transition could be robust prognostic and potential predictive biomarkers for standard and novel therapies. We analyzed in situ protein expression of E-cadherin (ECAD), integrin \u03b24 (ITGB4), zonula occludens 1 (ZO-1), and cytokeratins in a single-hospital series of Norwegian patients with colorectal cancer (CRC) stages I-IV (n = 922) using multiplex fluorescence-based immunohistochemistry (mfIHC) on tissue microarrays. Pharmacoproteomic associations were explored in 35 CRC cell lines annotated with drug sensitivity data on > 400 approved and investigational drugs. ECAD, ITGB4, and ZO-1 were positively associated with survival, while cytokeratins were negatively associated with survival. Only ECAD showed independent prognostic value in multivariable Cox models. Clinical and molecular associations for ECAD were technically validated on a different mfIHC platform, and the prognostic value was validated in another Norwegian series (n = 798). In preclinical models, low and high ECAD expression differentially associated with sensitivity to topoisomerase, aurora, and HSP90 inhibitors, and EGFR inhibitors. E-cadherin protein expression is a robust prognostic biomarker with potential clinical utility in CRC.", "doi": "10.1002/1878-0261.13159", "pmid": "34890102", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9208074"}], "notes": [], "created": "2026-08-20T06:26:46.053Z", "modified": "2026-08-20T06:26:46.155Z"}, {"entity": "publication", "iuid": "3b7256b32eb04365aedfd8a93d177870", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/3b7256b32eb04365aedfd8a93d177870.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/3b7256b32eb04365aedfd8a93d177870"}}, "title": "Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer.", "authors": [{"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}, {"family": "Sandeman", "given": "Kevin", "initials": "K", "orcid": "0000-0002-5019-6254", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/4714abc9cb0d4864b5f4e98e42c6d70d.json"}}, {"family": "Blom", "given": "Sami", "initials": "S"}, {"family": "Turkki", "given": "Riku", "initials": "R", "orcid": "0000-0002-8690-6983", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/74597043811c4f49bfe09812a9a5f3a4.json"}}, {"family": "Hemmes", "given": "Annabrita", "initials": "A"}, {"family": "V\u00e4lim\u00e4ki", "given": "Katja", "initials": "K"}, {"family": "Eineluoto", "given": "Juho", "initials": "J"}, {"family": "Kentt\u00e4mies", "given": "Anu", "initials": "A", "orcid": "0000-0002-3937-5307", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/764d375bb15f4c8384b69e04a04c2f1f.json"}}, {"family": "Nordling", "given": "Stig", "initials": "S", "orcid": "0000-0001-5555-6645", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/505f7449f490451eb5fd9ae5e5b5ff2c.json"}}, {"family": "Kallioniemi", "given": "Olli", "initials": "O", "orcid": "0000-0002-3231-0332", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cb8605b07c884323afe4e1f2da37a031.json"}}, {"family": "Rannikko", "given": "Antti", "initials": "A", "orcid": "0000-0002-4261-3484", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/6beb375af62740ec8ab9bb0e6ad52e48.json"}}, {"family": "Mirtti", "given": "Tuomas", "initials": "T", "orcid": "0000-0003-0455-9891", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/c1963bc5086f4b45b9a48cb60115d578.json"}}], "type": "journal article", "published": "2022-03-00", "journal": {"title": "Cancer Res Commun", "issn": "2767-9764", "volume": "2", "issue": "3", "pages": "172-181", "issn-l": null}, "abstract": "Some clinically significant prostate cancers are missed by MRI. We asked whether the tumor stroma in surgically treated localized prostate cancer lesions positive or negative with MRI are different in their cellular and molecular properties, and whether the differences are reflected to the clinical course of the disease. We profiled the stromal and immune cell composition of MRI-classified tumor lesions by applying multiplexed fluorescence IHC (mfIHC) and automated image analysis in a clinical cohort of 343 patients (cohort I). We compared stromal variables between MRI-visible lesions, invisible lesions, and benign tissue and assessed the predictive significance for biochemical recurrence (BCR) and disease-specific survival (DSS) using Cox regression and log-rank analysis. Subsequently, we carried out a prognostic validation of the identified biomarkers in a population-based cohort of 319 patients (cohort II). MRI true-positive lesions are different from benign tissue and MRI false-negative lesions in their stromal composition. CD163+ cells (macrophages) and fibroblast activation protein (FAP)+ cells were more abundant in MRI true-positive than in MRI false-negative lesions or benign areas. In MRI true-visible lesions, a high proportion of stromal FAP+ cells was associated with PTEN status and increased immune infiltration (CD8+, CD163+), and predicted elevated risk for BCR. High FAP phenotype was confirmed to be a strong indicator of poor prognosis in two independent patient cohorts using also conventional IHC. The molecular composition of the tumor stroma may determine whether early prostate lesions are detectable by MRI and associates with survival after surgical treatment.\n\nThese findings may have a significant impact on clinical decision making as more radical treatments may be recommended for men with a combination of MRI-visible primary tumors and FAP+ tumor stroma.", "doi": "10.1158/2767-9764.CRC-21-0183", "pmid": "36874403", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9980917"}, {"db": "pii", "key": "CRC-21-0183"}], "notes": [], "created": "2026-08-20T12:14:51.718Z", "modified": "2026-08-20T12:14:52.005Z"}, {"entity": "publication", "iuid": "c772d0857e5e4f559522e733765e6155", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c772d0857e5e4f559522e733765e6155.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c772d0857e5e4f559522e733765e6155"}}, "title": "Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.", "authors": [{"family": "Blom", "given": "Sami", "initials": "S"}, {"family": "Erickson", "given": "Andrew", "initials": "A"}, {"family": "\u00d6stman", "given": "Arne", "initials": "A"}, {"family": "Rannikko", "given": "Antti", "initials": "A"}, {"family": "Mirtti", "given": "Tuomas", "initials": "T"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}], "type": "journal article", "published": "2019-09-00", "journal": {"title": "Prostate", "issn": "1097-0045", "volume": "79", "issue": "13", "pages": "1505-1513", "issn-l": null}, "abstract": "Tumor stroma associates with prostate cancer (PCa) progression, but its specific cellular composition and association to patient survival outcome have not been characterized.\n\nWe analyzed stromal composition in human PCa using multiplex immunohistochemistry and quantitative, high-resolution image analysis in two retrospective, formalin-fixed paraffin embedded observational clinical cohorts (Cohort I, n = 117; Cohort II, n = 340) using PCa-specific mortality as outcome measurement.\n\nA high proportion of fibroblasts associated with aggressive disease and castration-resistant prostate cancer (CRPC). In a multivariate analysis, increase in fibroblast proportion predicted poor cancer-specific outcome independently in the two clinical cohorts studied.\n\nFibroblasts were the most important cell type in determining prognosis in PCa and associated with CRPC. Thus, the stromal composition could be critically important in developing diagnostic and therapeutic approaches to aggressive prostate cancer.", "doi": "10.1002/pros.23867", "pmid": "31269283", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6813917"}], "notes": [], "created": "2026-08-20T06:35:14.499Z", "modified": "2026-08-20T06:35:14.575Z"}, {"entity": "publication", "iuid": "c63e2dfc19124c239f8ea1edc6858e36", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c63e2dfc19124c239f8ea1edc6858e36.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c63e2dfc19124c239f8ea1edc6858e36"}}, "title": "Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.", "authors": [{"family": "Slik", "given": "Khadija", "initials": "K"}, {"family": "Blom", "given": "Sami", "initials": "S"}, {"family": "Turkki", "given": "Riku", "initials": "R"}, {"family": "V\u00e4lim\u00e4ki", "given": "Katja", "initials": "K"}, {"family": "Kurki", "given": "Samu", "initials": "S"}, {"family": "Mustonen", "given": "Harri", "initials": "H"}, {"family": "Haglund", "given": "Caj", "initials": "C"}, {"family": "Carp\u00e9n", "given": "Olli", "initials": "O"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Korkeila", "given": "Eija", "initials": "E"}, {"family": "Sundstr\u00f6m", "given": "Jari", "initials": "J"}, {"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}], "type": "journal article", "published": "2019-01-00", "journal": {"title": "J Pathol Clin Res", "issn": "2056-4538", "volume": "5", "issue": "1", "pages": "63-78", "issn-l": null}, "abstract": "Tumour budding predicts survival of stage II colorectal cancer (CRC) and has been suggested to be associated with epithelial-to-mesenchymal transition (EMT). However, the underlying molecular changes of tumour budding remain poorly understood. Here, we performed multiplex immunohistochemistry (mIHC) to phenotypically profile tumours using known EMT-associated markers: E-cadherin (adherence junctions), integrin \u03b24 (ITGB4; basement membrane), ZO-1 (tight junctions), and pan-cytokeratin. A subpopulation of patients showed high ITGB4 expression in tumour buds, and this coincided with a switch of ITGB4 localisation from the basal membrane of intact epithelium to the cytoplasm of budding cells. Digital image analysis demonstrated that tumour budding with high ITGB4 expression in tissue microarray (TMA) cores correlated with tumour budding assessed from haematoxylin and eosin (H&E) whole sections and independently predicted poor disease-specific survival in two independent stage II CRC cohorts (hazard ratio [HR] = 4.50 (95% confidence interval [CI] = 1.50-13.5), n = 232; HR = 3.52 (95% CI = 1.30-9.53), n = 72). Furthermore, digitally obtained ITGB4-high bud count in random TMA cores was better associated with survival outcome than visual tumour bud count in corresponding H&E-stained samples. In summary, the mIHC-based phenotypic profiling of human tumour tissue shows strong potential for the molecular characterisation of tumour biology and for the discovery of novel prognostic biomarkers.", "doi": "10.1002/cjp2.119", "pmid": "30358171", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6317060"}], "notes": [], "created": "2026-08-20T06:31:18.111Z", "modified": "2026-08-20T06:31:18.173Z"}]}